Albert Bourla，2014年1月担任一家肿瘤学和消费者保健公司，疫苗的集团总裁。2010年12月到2013年12月担任既定产品业务部门的董事长和总经理。2009年到2010年11月担任Pfizer动物保健欧洲，非洲，亚洲和太平洋地区的总裁。2005年到2009年担任Pfizer动物保健欧洲，非洲和中东地区的总裁。

Albert Bourla,is Chairman of the Board of Pfizer since January 2020; Chief Executive Officer of Pfizer since January 2019; Chief Operating Officer of Pfizer from January 2018 until December 2018; Group President, Pfizer Innovative Health from June 2016 until December 2017; Group President, Global Innovative Pharma Business of Pfizer from February 2016 until June 2016 (responsible for Vaccines, Oncology and Consumer Healthcare from 2014). President and General Manager of Established Products Business Unit of Pfizer from 2010 until 2013. Chair of the Board of PhRMA and Chair of the Board of The Pfizer Foundation, which promotes access to quality healthcare. Co-Chair of the Board of Directors of the Partnership for New York City and Member of the Board of Catalyst.

Lidia Fonseca，首席数字和技术官，自2019年1月起担任执行副总裁。2014-2018年担任奎斯特诊疗公司首席信息官兼高级副总裁。2008年至2013年3月任美国实验室公司控股高级副总裁。美敦力有限公司董事。

Lidia Fonseca,is the Chief Digital and Technology Officer and Executive Vice President of Pfizer, Inc. where she is responsible for enterprise-wide digital, data and technology strategy, products and solutions, Learning and Development and Business Process Excellence functions, as well as the Digital Health and Medicines unit. Prior to her current role, she served as the Senior Vice President and Chief Information Officer (CIO) at Quest Diagnostics from 2014 to 2018. Previously, she served as the Senior Vice President and CIO at LabCorp from 2008 to 2013. Ms. Fonseca has received many awards and accolades, and most recently, was named to the list of Most Powerful Latinas in 2020, 2021 and 2022 by the Association of Latino Professionals for America; received the 2023 National CIO of the Year ORBIE Award; was named on the 2022 Forbes CEO Next List recognizing top 50 executives who are likely to lead America's top companies and the 2022 Forbes CIO Next List recognizing the top 50 tech leaders who are redefining the CIO role and driving game-changing innovation.

Payal Sahni，首席人力资源官，自2020年6月起担任执行副总裁。2016年5月至2020年6月，担任多个运营单位的人力资源高级副总裁。2015年至2016年任人力资源、疫苗、肿瘤和消费者副总裁。自1997年加入辉瑞公司以来，Sahni女士在人力资源组织担任了多个职位，责任越来越重。

Payal Sahni,Chief People Experience Officer, Executive Vice President since January 2022. Chief Human Resources Officer, Executive Vice President from June 2020 to December 2021. From May 2016 until June 2020 served as Senior Vice President of Human Resources for multiple operating units. Vice President of Human Resources, Vaccines, Oncology & Consumer from 2015 until 2016. Ms. Sahni has served in a number of positions in the Human Resources organization with increasing responsibility since joining Pfizer in 1997.

Aamir Malik，首席商业创新官，执行副总裁自2021年8月。麦肯锡公司2019至2021年间在美国的各种领导角色；曾于2015年至2018年共同领导麦肯锡公司的全球药品和医疗产品业务。

Aamir Malik,Chief U.S. Commercial Officer, Executive Vice President since December 2023. Chief Business Innovation Officer, Executive Vice President from August 2021 until December 2023. Various U.S. geographic leadership roles with McKinsey & Company from 2019 to 2021; previously co-led McKinsey & Company's Global Pharmaceuticals & Medical Products practice from 2015 to 2018.

Michael McDermott，全球首席供应和质量官，自2025年1月起担任执行副总裁。首席全球供应官，2022年至2024年12月任执行副总裁。2018年至2021年任辉瑞全球供应总裁。2014年至2018年任辉瑞全球供应副总裁。2012年至2014年担任生物技术股副总裁。

Michael McDermott,Chief Global Supply and Quality Officer, Executive Vice President since January 2025. Chief Global Supply Officer, Executive Vice President from 2022 until December 2024. President of Pfizer Global Supply from 2018 until 2021. Vice President of Pfizer Global Supply from 2014 until 2018. Vice President of the Biotechnology Unit from 2012 until 2014.

Chris Boshoff，首席肿瘤学官，自2023年12月起担任执行副总裁。2023年7月至2023年12月任首席肿瘤学研发官兼执行副总裁。肿瘤学高级副总裁，2017年至2023年。

Chris Boshoff,Chief Scientific Officer and President, Research & Development, since January 2025. Chief Oncology Officer, Executive Vice President from December 2023 until December 2024. Chief Oncology Research and Development Officer and Executive Vice President from July 2023 until December 2023. Senior Vice President, Oncology, from 2017 until 2023.

Alexandre de Germay，首席国际商务官，自2023年12月起任执行副总裁。Laboratoires Majorelle（一家位于法国、致力于女性健康和泌尿外科的专业制药公司）首席执行官，2021年至2024年1月（2023年12月15日之后协助过渡事宜）。2020年至2021年任高级副总裁；心脏病学、移植和成熟产品全球特许经营负责人，2016年至2020年任赛诺菲成熟市场普药负责人。2013年至2016年任辉瑞公司亚太区域总裁。

Alexandre de Germay,Chief International Commercial Officer, Executive Vice President since December 2023. Chief Executive Officer, Laboratoires Majorelle (a specialty pharma company based in France dedicated to women's health and urology) from 2021 until January 2024 (assisting with transition matters after December 15, 2023). From 2020 until 2021 was Senior Vice President; Global Franchise Head of Cardiology, Transplant and Established Products, and from 2016 until 2020 was Head of Mature Markets General Medicines of Sanofi. Regional President of Asia-Pacific of Pfizer Inc. from 2013 until 2016.

Andrew Baum，自2024年起担任首席战略与创新官兼执行副总裁。在加入辉瑞之前，他从2011年到2024年担任花旗集团全球医疗保健主管-董事总经理股票研究。

Andrew Baum,Chief Strategy and Innovation Officer and Executive Vice President since 2024. Prior to joining Pfizer, he was Head of Global Healthcare - Managing Director Equity Research at Citigroup from 2011 until 2024.

David M. Denton，他自2010年1月起担任CVS Caremark公司执行副总裁兼首席财务官；2008年3月至2009年12月，曾任CVS Caremark Corporation的高级副总裁兼总监/首席会计官；2007年4月至2008年3月，曾任CVS Caremark Corporation高级副总裁，财务管理的CVS Caremark公司和CVS Health Corporation。

David M. Denton,Chief Financial Officer, Executive Vice President since May 2022. Executive Vice President, Chief Financial Officer, Lowe's Companies, Inc., from November 2018 until April 2022; Executive Vice President and Chief Financial Officer, CVS Health Corporation (a diversified health solutions company), from January 2010 until November 2018. Served as Director of Haleon plc from March 2023 to December 2024.

Douglas M. Lankler，2013年12月担任执行副总裁和法律总顾问。2014年1月到2014年2月担任公司秘书。2011年2月到2013年12月担任执行副总裁，首席合规和风险官。2010年12月到2011年2月担任执行副总裁，首席合规官。2010年1月到2010年12月担任高级副总裁和首席合规官。2009年8月至2010年1月担任高级副总裁，副顾问和首席合规官。2006年10月到2009年8月担任高级副总裁，法律副顾问和首席合规官。

Douglas M. Lankler,Chief Legal Officer, Executive Vice President since January 2025. General Counsel, Executive Vice President from December 2013 until December 2024. Corporate Secretary from January 2014 until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013.

Albert Bourla，2014年1月担任一家肿瘤学和消费者保健公司，疫苗的集团总裁。2010年12月到2013年12月担任既定产品业务部门的董事长和总经理。2009年到2010年11月担任Pfizer动物保健欧洲，非洲，亚洲和太平洋地区的总裁。2005年到2009年担任Pfizer动物保健欧洲，非洲和中东地区的总裁。

Albert Bourla,is Chairman of the Board of Pfizer since January 2020; Chief Executive Officer of Pfizer since January 2019; Chief Operating Officer of Pfizer from January 2018 until December 2018; Group President, Pfizer Innovative Health from June 2016 until December 2017; Group President, Global Innovative Pharma Business of Pfizer from February 2016 until June 2016 (responsible for Vaccines, Oncology and Consumer Healthcare from 2014). President and General Manager of Established Products Business Unit of Pfizer from 2010 until 2013. Chair of the Board of PhRMA and Chair of the Board of The Pfizer Foundation, which promotes access to quality healthcare. Co-Chair of the Board of Directors of the Partnership for New York City and Member of the Board of Catalyst.

James C. Smith，2012年1月以来，他担任Thomson Reuters Corporation（为企业和专业人士提供智能信息的供应商）的总裁和首席执行官以及董事。从2011年9月到2011年12月，他担任其首席运营官。从2008年到2011年，他担任Thomson Reuters Professional部门首席执行官。2008年Reuters Group PLC被The Thomson Corporation （Thomson）收购之前，他担任Thomson的首席运营官和Thomson Learning的学术和参照部门的总裁兼首席执行官。

James C. Smith,is Chairman of the Thomson Reuters Foundation, a London-based charity supported by Thomson Reuters. President and Chief Executive Officer of Thomson Reuters, a provider of intelligent information for businesses and professionals from 2012 through March 2020, its Chief Operating Officer from September 2011 to December 2011, and Chief Executive Officer, Thomson Reuters Professional Division, from 2008 to 2011. Prior to the acquisition of Reuters Group PLC by The Thomson Corporation in 2008, served as Chief Operating Officer of Thomson Corporation and as President and Chief Executive Officer of Thomson Learning's Academic and Reference Group. Director of Refinitiv, a privately held global provider of financial market data and infrastructure until its acquisition by the London Stock Exchange Group in January 2021. Member of the Board of Governors of Marshall University. Member of the Board of Trustees of the Brookings Institution. Director of Thomson Reuters from 2012 until 2020.

Joseph J. Echevarria，从2011年一直到2014年退休前，在一家全球专业化服务的提供商- Deloitte LLP担任首席执行官。在该公司的36年职业生涯中，曾担任高级职位，不断被提升到重要的位置上，包括被任命为首席执行官之前，担任美国业务一般合伙人。他目前在Miami大学Private Export Council、国际贸易主要国家咨询委员会的理事会任职。还曾被总统奥巴马（Obama）任命为一家旨在想方设法为企业和公民领袖授权男孩和色彩年轻人的联邦机构- My Brother’s Keeper的联席主席。持有Miami大学的工商管理学士学位。

Joseph J. Echevarria served as CEO of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. Mr. Echevarria previoly served in increasingly senior leadership positions during his 36 year career at the firm, including U.S. Managing Partner for Operations, prior to being named CEO.In addition to his current public company board service, Mr. Echevarria serves as a President and CEO of the University of Miami and President of the University of Miami Health System. Mr. Echevarria served as a director of Xerox Corporation from 2017 until 2023. Mr. Echevarria previoly served as Chairman of President Obama's My Brother's Keeper Alliance and as a Member of the Private Export Council, the principal national advisory committee on international trade. Mr. Echevarria earned his bachelor's degree in biness administration from the University of Miami.

Cyrus Taraporevala于2016年4月加入道富，自2017年11月起担任道富 Global Advisors总裁兼首席执行官。他加入道富 Global Advisors，担任执行副总裁兼产品和营销全球主管。在加入道富 Global Advisors之前，Taraporevala先生于2012年至2015年10月担任富达投资的零售管理账户和人寿保险与年金主管。在此之前，Taraporevala先生曾在纽约梅隆银行资产管理公司担任高级领导职务，包括北美分销执行董事。

Cyrus Taraporevala,is President and Chief Executive Officer of State Street Global Advisors from 2017 until 2022. Previously, held a variety of senior leadership roles at State Street Global Advisors, including responsibility for leading the global institutional client, product and marketing teams. Prior to joining State Street Advisors, held numerous leadership roles in asset management including at Fidelity Investments, The Bank of New York Mellon Corporation, Legg Mason Inc., and Citigroup Inc. Spent 14 years at McKinsey & Company, the management consulting firm. Director of Shell plc. Also serves as a Director of Bridgepoint Group plc, a London-based international alternative asset fund management group. Member of the Board of Trustees of two not-for-profit organizations: GBH, a public media broadcaster, and The Trustees of Reservations, a Massachusetts-based land conservation organization.

Dan R. Littman、Helen L。和Martin S.Kimmel自1995年起任纽约大学兰贡医学中心Skirball生物分子医学研究所分子免疫学教授，1987年起任霍华德休斯医学研究所研究员。1985年至1995年，加利福尼亚大学旧金山分校微生物学和免疫学教授。国家科学院和国家医学院院士。美国艺术科学院和美国微生物学院院士。Vedanta Biosciences的创始科学顾问委员会成员，Immunai，Inc.的科学联合创始人和顾问委员会成员。Chemicentryx，Inc.的科学顾问委员会成员，MGH、麻省理工学院和哈佛大学的癌症研究所、博德研究所和拉贡研究所。帕克癌症免疫治疗研究所科学指导委员会成员。荣获2004年纽约市市长科学技术杰出奖、2013年罗斯分子医学奖和2016年维尔切克生物医学奖。

Dan R. Littman,is Helen L. and Martin S. Kimmel Professor of Molecular Immunology, Department of Pathology at NYU Grossman School of Medicine (NYU Grossman). Professor, Department of Microbiology at NYU Grossman since 1995 and Investigator, Howard Hughes Medical Institute, since 1987. Professor of Microbiology and Immunology at the University of California, San Francisco from 1985 to 1995. Member of the National Academy of the Sciences and the National Academy of Medicine. Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology. Founding Scientific Advisory Board Member of Vedanta Biosciences and Scientific co-founder and Advisory Board Member of Immunai, Inc. Member of Scientific Advisory Boards at the Cancer Research Institute, the Broad Institute, IMIDomics, Scleroderma Research Foundation, Sonoma Biotherapeutics, Whitehead Institute of MIT Board of Advising Scientists and the Ragon Institute of MGH, MIT and Harvard. Member of the Scientific Steering Committee of Parker Institute of Cancer Immunotherapy. Awarded the New York City Mayor's Award for Excellence in Science and Technology (2004), the Ross Prize in Molecular Medicine (2013), the Vilcek Prize in Biomedical Science (2016), and the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (2016).

Susan Desmond Hellmann是Bill & Melinda Gates基金会的首席执行官，Bill & Melinda Gates基金会致力于加强全球医疗保健，减少极端贫困和扩大教育机会，从2014年到2020年退休，目前继续担任盖茨医学研究所的高级顾问和董事会成员。在加入Bill & Melinda Gates 基金会之前，她曾在2009年至2014年担任加州大学旧金山分校的第一位女校长和第九位总校长。Hellmann博士仍然是加州大学旧金山分校的兼职教授。1995年至2009年，Desmond Hellmann博士受雇于Genentech，2005年至2009年担任产品开发总裁，负责临床前和临床开发、业务开发和产品组合管理。在加入Genentech之前，她是百时美施贵宝制药研究所临床癌症研究副主任。2013年至2019年担任Facebook公司董事。2010年至2017年担任宝洁董事。

Susan Desmond Hellmann,is Board member of OpenAI, National Resilience, Inc. and Stand Up To Cancer. Senior Advisor at Lazard, Inc. in the Healthcare Group. Senior Advisor at GMRI from 2020 to 2021. CEO of the Bill & Melinda Gates Foundation, a private foundation committed to enhancing global healthcare, reducing extreme poverty and expanding educational opportunities, from 2014 to 2020. She served as the first female, and ninth overall, Chancellor of UCSF from 2009 to 2014. Dr. Desmond-Hellmann remains an Adjunct Professor at UCSF. Member of the President's Council of Advisors on Science and Technology. From 1995 through 2009, she was employed at Genentech where she served as President of Product Development from 2005 to 2009, overseeing pre-clinical and clinical development, business development and product portfolio management. Prior to Genentech, she was Associate Director, Clinical Cancer Research at Bristol-Myers Squibb Pharmaceutical Research Institute. Director of: (i) Meta from 2013 to 2019; and (ii) Procter & Gamble from 2010 to 2017. Received the Hockfield Cancer Research Prize (2023).

James Quincey，The Coca-Cola Company，自2019年4月起担任董事长，自2017年5月起担任首席执行官，2015年8月至2018年12月担任总裁，2015年8月至2017年4月担任首席运营官，2013年1月至2015年8月担任欧洲集团总裁，2008年10月至2013年1月担任西北欧总裁和Nordics业务单元总裁。2005年12月至2008年10月墨西哥部门总裁。2003年12月至2005年12月南拉丁部门总裁。1996年加入公司担任拉丁美洲集团学习战略总监，并继续在拉丁美洲担任一系列职责不断增加的运营角色。美中贸易委员会主任兼促使变化的人。商业圆桌会议成员。

James Quincey Chairman of the Board of Directors since April 2019 and Chief Executive Officer since May 2017. Elected to the Board of Directors in April 2017. President from Augt 2015 to December 2018, and Chief Operating Officer from Augt 2015 to April 2017. He will step down as Chief Executive Officer effective March 31, 2026, on which date he will transition to Executive Chairman.

Mortimer J. Buckley，从2018年起担任Vanguard的董事长兼首席执行官，直到2024年退休。此前，他是Vanguard的首席投资官，负责监督公司内部管理的股票、债券和货币市场投资组合以及投资研究和方法论。Buckley先生于1991年加入Vanguard，担任过多个高级领导职务，包括首席信息官和零售投资者集团负责人。在Vanguard之外，他于2011年至2017年担任费城儿童医院董事会主席。Buckley先生获得哈佛学院经济学文学学士学位和哈佛商学院工商管理硕士学位。

Mortimer J. Buckley,is Chairman and Chief Executive Officer of Vanguard from 2018 to 2024. Previously, held a number of senior leadership positions at Vanguard, including Vanguard's Chief Investment Officer from 2013 to 2017, overseeing the company's managed stock, bond and money market portfolios as well as its investment research and methodology, and Chief Information Officer from 2001 to 2006. In addition, led Vanguard's Personal Investor division from 2006 to 2012. Served as Chairman of the Board of Children's Hospital of Philadelphia from 2011 to 2017. Director of The Boeing Company.

Shantanu Narayen，Adobe公司的董事长兼首席执行官，Adobe公司是世界上最大、最多元化的软件公司之一。Adobe总裁至2021年12月。在2007年被任命为首席执行官之前，他曾在Adobe担任多个领导职务，包括总裁兼首席运营官，全球产品部执行副总裁，全球产品开发部高级副总裁。美印战略伙伴关系论坛副主席。一直被《巴伦周刊》评为全球最佳CEO之一，并在2020年被《财富》杂志评为“年度最佳企业家”。

Shantanu Narayen currently serves as Chief Executive Officer and Chair of the Board. He joined Adobe in January 1998 as Vice President and General Manager of engineering technology group. In January 1999, he was promoted to Senior Vice President, Worldwide Products, and in March 2001, he was promoted to Executive Vice President, Worldwide Product Marketing and Development. In January 2005, Mr. Narayen was promoted to President and Chief Operating Officer, and effective December 2007, he was appointed Chief Executive Officer and joined Board. In January 2017, he was named Chair of the Board. Mr. Narayen holds a B.S. in Electronics Engineering from Osmania University in India, an M.S. in Computer Science from Bowling Green State University and an M.B.A. from the Haas School of Biness, University of California, Berkeley.

Scott Gottlieb，他自2009年1月起担任New Enterprise Associates，Inc.董事，从2019年起为美国企业研究所的常驻研究员。也是在纽约大学医学院的医学临床助理教授。从2005年到2007年，曾在美国食品和药物管理局“FDA”担任副处长，负责医学和科学事务。在此之前，从2003年到2004年担任FDA局长的医疗技术高级顾问和医疗FDA政策发展的董事。于2004年春离开了美国FDA，去完成新的医疗保险药物报销的工作，作为医疗保险和医疗补助服务中心的高级顾问，支持运用相关新的医疗技术，提高质量和覆盖范围和支付决策机构的政策工作。目前担任Molecular Insight Pharmaceuticals的董事。国家医学院院士，财经新闻网CNBC撰稿人，是Sinai School of Medicine和Connecticut Wesleyan University的毕业生。

Scott Gottlieb,has been a director since February 2020. Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. He was elected Chairman of the Board of Directors in March 2025. He is currently a Special Partner at the venture capital firm New Enterprise Associates and a Resident Fellow at the American Enterprise Institute for Public Policy Research, and he serves as a director of Pfizer, Aetion, Tempus Labs, National Resilience and the Mount Sinai Medical System. Dr. Gottlieb held several roles in the public and private sectors prior to serving as FDA Commissioner, including serving as a venture partner at New Enterprise Associates from 2007 to 2017. Dr. Gottlieb was previously the FDA's Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as a senior advisor to the FDA Commissioner from 2003 to 2004. He was also a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004. Dr. Gottlieb has advised the states of Massachusetts, Maryland, and Montana on the Covid response as a member of state advisory boards. He is a contributor to CNBC and CBS Face the Nation.Dr. Gottlieb received a B.A. in economics from Wesleyan University and his M.D. from the Icahn School of Medicine at Mount Sinai.

Suzanne Nora Johnson，高盛集团：1985年至2007年担任多个管理职位，包括副主席、全球市场研究所主席和全球投资研究部主管。Nora Johnson从2007年到2022年担任VISA Inc.的董事会成员，在那里她是提名和治理委员会以及审计和风险委员会的成员；从2008年到2020年担任美国国际集团（American International Group, Inc.）的董事会成员，在那里她是风险和资本委员会主席，提名和公司治理委员会和技术委员会的成员。其他职务：布鲁金斯学会联合主席。马克尔基金会董事会主席。南加州大学校董会主席。学历：南加州大学文学学士。哈佛法学院法学博士。其他上市公司董事会：Pfizer Inc.（自2007年起担任审计委员会主席，并在监管与合规委员会和执行委员会任职）。

Suzanne Nora Johnson,Retired Vice Chairman, Goldman Sachs, since 2007. During her 21-year tenure with Goldman Sachs, she served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Health Care. Board Chair of Intuit Inc.; Co-Chair, Board of Trustees of The Brookings Institution; Member of the Board of Trustees of the Carnegie Institution of Washington; and Chair of the Board of Trustees of the University of Southern California. Member of the American Academy of Arts and Sciences. Director of American International Group, Inc. from 2008 to 2020 and Visa, Inc. from 2007 to 2022.

Ronald E. Blaylock，他是GenNx360 Capital Partners（一家私募股权公司，自2006年以来专注于投资美国中型市场的工业和商业服务公司）的创始人和管理合伙人。在推出GenNx360 Capital Partners之前，他创立并管理Blaylock & Company（一家投资银行公司）。他还曾在UBS、PaineWebber Group和Citicorp担任高级管理职务。CarMax, Inc.和W.R. Berkley Corporation（一家保险控股公司）董事。Advantage Solutions Inc.（从2019年到2022年）和Urban One， Inc.（从2002年到2019年）的前董事。卡内基音乐厅董事会成员。纽约大学斯特恩商学院监事会成员。精神健康联盟董事会成员。

Ronald E. Blaylock Founder and Managing Partner of GenNx360 Capital Partners, a private equity buyout firm, since 2006. Between 1993 and 2006, Mr. Blaylock was the Founder, Chairman and Chief Executive Officer of Blaylock & Company, Inc., an investment banking firm. Prior to that, he held senior management positions with PaineWebber Group and Citicorp. He currently serves on the Board of Pfizer, Inc. He previously served on the Boards of CarMax, Inc. and Advantage Solutions Inc. He is currently a Trustee of Carnegie Hall and the New York University Stern School of Business. He was a Director of Urban One, Inc. until 2019, and formerly served on the Board of Trustees of Georgetown University, American Ballet Theater, Covenant House, National Association of Basketball Coaches, Prep for Prep, Inner City Scholarship Fund and the Mebane Foundation.